Arrivent Biopharma, INC. (AVBP) — 8-K Filings

8-K Filings (14)

• ArriVent BioPharma Files 8-K — Sep 9, 2025 Risk: low
  On September 9, 2025, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial stateme
• ArriVent BioPharma Files 8-K Report — Jul 21, 2025 Risk: low
  On July 21, 2025, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
• ArriVent BioPharma Enters Material Definitive Agreement — Jul 2, 2025 Risk: medium
  On July 1, 2025, ArriVent BioPharma, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offic
• ArriVent BioPharma Files 8-K — Jun 23, 2025 Risk: low
  ArriVent BioPharma, Inc. filed an 8-K on June 23, 2025, reporting on other events and financial statements. The filing does not contain specific financial figur
• ArriVent BioPharma Files 8-K on Shareholder Vote Matters — Jun 20, 2025 Risk: low
  ArriVent BioPharma, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of security holders on June 18, 2025. The filing details the co
• ArriVent BioPharma Elects New Directors, Discloses Officer Compensation — Apr 28, 2025 Risk: low
  On April 23, 2025, ArriVent BioPharma, Inc. announced the election of Dr. Jonathan Lim and Mr. David E. Johnson to its Board of Directors. The company also disc
• ArriVent BioPharma Changes Auditors — Mar 13, 2025 Risk: low
  ArriVent BioPharma, Inc. announced on March 11, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new ind
• ArriVent BioPharma Enters Material Definitive Agreement — Jan 22, 2025 Risk: medium
  On January 21, 2025, ArriVent BioPharma, Inc. entered into a material definitive agreement. The company also disclosed information under Regulation FD and filed
• ArriVent BioPharma Files 8-K Report — Sep 9, 2024 Risk: low
  On September 9, 2024, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no s
• ArriVent BioPharma Enters Material Definitive Agreement — Jun 5, 2024 Risk: medium
  On June 4, 2024, ArriVent BioPharma, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statemen
• ArriVent BioPharma Appoints New CMOs — May 16, 2024 Risk: low
  On May 16, 2024, ArriVent BioPharma, Inc. announced the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and Dr. Michael J. Zelefsky as Chief Medi
• ArriVent Biopharma Appoints New CMO, Elects Director — Apr 22, 2024 Risk: medium
  ArriVent Biopharma, Inc. announced on April 20, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and the election of Ms. Sarah E. Kelly
• ArriVent Biopharma Files 8-K on Financials — Mar 28, 2024 Risk: low
  On March 28, 2024, ArriVent Biopharma, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• ArriVent Biopharma Files 8-K for Bylaw Amendments, Other Events — Jan 30, 2024
  ArriVent Biopharma, Inc. filed an 8-K on January 30, 2024, to report an amendment to its Articles of Incorporation or Bylaws, along with other events and financ

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX